301. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis
- Author
-
Robert J. Ignoffo and Alexandre Chan
- Subjects
Mucositis ,medicine.medical_specialty ,Nystatin ,Magnesium Hydroxide ,Adrenal cortex hormones ,Drug Compounding ,Mouthwashes ,Dentistry ,Aluminum Hydroxide ,03 medical and health sciences ,0302 clinical medicine ,Drug Utilization Review ,Adrenal Cortex Hormones ,Surveys and Questionnaires ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Oral solutions ,Drug compounding ,business.industry ,Magic Mouthwash ,Administration, Buccal ,Lidocaine ,Reproducibility of Results ,Buccal administration ,medicine.disease ,Dermatology ,Diphenhydramine ,Oncology ,030220 oncology & carcinogenesis ,Pharmaceutical Services ,business ,Mouth Diseases ,030215 immunology - Abstract
Purpose. The objectives of this study were (1) to describe the usage of topical oral solutions in patients experiencing chemotherapy-induced oral mucositis (CIOM); and (2) to survey the care of oral mucositis provided to patients by clinical oncology pharmacists in institutional settings. Methods. Surveys were distributed to institutional pharmacists in the US, who were asked to provide the components of their ‘magic mouthwash’. Other questions included whether an institutional mucositis management guideline is available and what is the involvement of clinical pharmacy in mucositis care. Results. Forty institutions returned surveys during the study period. The top five ingredients used to compound the magic mouthwash are diphenhydramine, viscous lidocaine, magnesium hydroxide/aluminum hydroxide, nystatin and corticosteroids. Most institutions administer the mouthwash every 4 hours (36%) or every 6 hours (36%). Of the surveyed institutions, 33% currently possess guidelines for the management of CIOM. Conclusions. Most institutions in the country formulate their topical solution, or magic mouthwash, with a variety of ingredients. There is a need to standardize the ingredients used to compound the magic mouthwash, in order to fully evaluate the efficacy of the solution to manage CIOM. more...
- Published
- 2006